Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease - PubMed (original) (raw)
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease
Ken Takeuchi et al. Clin Gastroenterol Hepatol. 2006 Feb.
Abstract
Background & aims: It has been variably suggested that nonselective NSAIDs and cyclooxygenase (COX)-2 selective inhibitors aggravate or ameliorate clinical disease activity in patients with inflammatory bowel disease. We assessed the effect of these drugs in patients with inflammatory bowel disease (n = 209) and the possible mechanisms.
Methods: First, patients with quiescent Crohn's disease and ulcerative colitis received the non-NSAID analgesic acetaminophen (n = 26) and the conventional NSAIDs naproxen (n = 32), diclofenac (n = 29), and indomethacin (n = 22) for 4 weeks. The Harvey-Bradshaw index was used to define relapse. Second, to assess the mechanism of relapse, intestinal inflammation was quantitated (fecal calprotectin) before and during treatment (20 patients/group) with acetaminophen, naproxen (topical effect, COX-1 and -2 inhibitor), nabumetone (COX-1 and -2 inhibitor), nimesulide (selective COX-2 inhibitor), and low-dose aspirin (selective COX-1 inhibition).
Results: Nonselective NSAIDs were associated with a 17%-28% relapse rate within 9 days of ingestion. No patient had an early relapse on acetaminophen, nimesulide, or aspirin, whereas those on naproxen and nabumetone (20%) experienced relapse. These clinical relapses were associated with escalating intestinal inflammatory activity.
Conclusions: NSAID ingestion is associated with frequent and early clinical relapse of quiescent inflammatory bowel disease, and the mechanism appears to be due to dual inhibition of the COX enzymes. Selective COX-2 inhibition with nimesulide and COX-1 inhibition with low-dose aspirin appear to be well-tolerated in the short-term.
Comment in
- Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
Korzenik JR, Podolsky DK. Korzenik JR, et al. Clin Gastroenterol Hepatol. 2006 Feb;4(2):157-9. doi: 10.1016/j.cgh.2005.11.007. Clin Gastroenterol Hepatol. 2006. PMID: 16469674 No abstract available.
Similar articles
- Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
Kvasnovsky CL, Aujla U, Bjarnason I. Kvasnovsky CL, et al. Scand J Gastroenterol. 2015 Mar;50(3):255-63. doi: 10.3109/00365521.2014.966753. Epub 2014 Oct 14. Scand J Gastroenterol. 2015. PMID: 25314574 Review. - Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Kefalakes H, et al. Eur J Clin Pharmacol. 2009 Oct;65(10):963-70. doi: 10.1007/s00228-009-0719-3. Epub 2009 Aug 27. Eur J Clin Pharmacol. 2009. PMID: 19711064 Review. - Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E, Nedjar H. Rahme E, et al. Rheumatology (Oxford). 2007 Mar;46(3):435-8. doi: 10.1093/rheumatology/kel428. Epub 2007 Jan 25. Rheumatology (Oxford). 2007. PMID: 17255138 - Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity.
Confino-Cohen R, Goldberg A. Confino-Cohen R, et al. Allergy Asthma Proc. 2003 Jul-Aug;24(4):281-4. Allergy Asthma Proc. 2003. PMID: 12974196 Clinical Trial.
Cited by
- Risk of Adverse Cardiovascular Outcomes in Postmenopausal Women with Inflammatory Bowel Disease.
Greywoode R, Larson J, Peraza J, Clark R, Allison MA, Chaudhry NA, Schnatz PF, Shadyab AH, Wallace RB, Wassertheil-Smoller S. Greywoode R, et al. Dig Dis Sci. 2024 Jul;69(7):2586-2594. doi: 10.1007/s10620-024-08348-2. Epub 2024 Apr 29. Dig Dis Sci. 2024. PMID: 38684633 Free PMC article. - Chronic abdominal pain in inflammatory bowel disease: a practical guide.
Baillie S, Norton C, Saxena S, Pollok R. Baillie S, et al. Frontline Gastroenterol. 2023 Oct 11;15(2):144-153. doi: 10.1136/flgastro-2023-102471. eCollection 2024. Frontline Gastroenterol. 2023. PMID: 38420131 Free PMC article. Review. - Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease.
Oka A, Kawashima K, Kishimoto K, Kotani S, Fukunaga M, Fukuba N, Mishima Y, Oshima N, Ishimura N, Awoniyi M, Ishihara S. Oka A, et al. Sci Rep. 2024 Jan 18;14(1):1653. doi: 10.1038/s41598-024-51580-z. Sci Rep. 2024. PMID: 38238442 Free PMC article. - The impact of aspirin use on outcomes in patients with inflammatory bowel disease: Insights from a national database.
Iqbal H, Arora GS, Singh I, Kohli I, Chaudhry H, Sohal A, Prajapati D. Iqbal H, et al. Int J Colorectal Dis. 2023 Dec 20;39(1):6. doi: 10.1007/s00384-023-04575-7. Int J Colorectal Dis. 2023. PMID: 38117356 Free PMC article. - Occurrence of adult-onset Still's disease after coronavirus disease 2019 BNT162B2 vaccination in a patient with ulcerative colitis: A case report and review of literature.
Kobayashi T, Hashimoto K, Kusanagi Y, Tanaka Y. Kobayashi T, et al. Clin Case Rep. 2023 Dec 5;11(12):e8298. doi: 10.1002/ccr3.8298. eCollection 2023 Dec. Clin Case Rep. 2023. PMID: 38076011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials